It was found that when transgenic BRAFV600E/WT P53−/− mice were treated with BRAF inhibitor PLX4720 and PD-L1 antibody the combination treatment strongly decreased tumor volume compared to single treatment through increased anti-tumor immune response [61]. Here, BRAF is linked to neoplasm.